sglt2 inhibitors vs glp 1 agonists Complementary Yet Distinct Roles of GLP-1 Receptor and in Cardiovascular Risk Reduction sglt2 inhibitors and glp-1 receptor

doi: 10.1016/j.cobeha.2015.12.004

Targeting PCSK9 to tackle cardiovascular disease

Most adverse events were mild to moderate GI symptoms, consistent with the known class effects of GLP-1based agents. Jastreboff et al., NEJM Additional Observations Some participants experienced a mild increase in resting heart rate similar to other GLP-1 drugs No serious hypoglycemia was observed unless combined with insulin or sulfonylureas A small number reported transient increases in liver enzymes , which normalized No increase in gallbladder events or pancreatitis noted compared to placebo Overall discontinuation rates were low (under 10%) How to Support Tolerance Naturally Stacking Retatrutide (once approved) with lifestyle and supplement support may enhance tolerability: Use Krill Oil to combat inflammation and improve lipid profiles Support gut health with Probiotics to reduce GI discomfort Ensure adequate hydration and electrolytes via INTRA during training or fasted cardio While Retatrutide is still investigational, early trials suggest its no more difficult to tolerate than Semaglutide or Tirzepatide and for many, the results may far outweigh the adjustment phase

Bayramolu and similar coastal settlements exemplify the impact of urban growth on rural and natural areas

Address Deficiency: Prescribe medication if applicable from consultation

A few days after initiating these therapies he actually felt worse, and developed high blood pressure with 170/120 blood pressure, and had to stop the supplements